Compare PMN & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMN | UG |
|---|---|---|
| Founded | 2004 | 1942 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 27.7M |
| IPO Year | N/A | N/A |
| Metric | PMN | UG |
|---|---|---|
| Price | $14.61 | $6.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $42.67 | N/A |
| AVG Volume (30 Days) | ★ 442.7K | 14.9K |
| Earning Date | 03-30-2026 | 03-20-2026 |
| Dividend Yield | N/A | ★ 7.47% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $10,060,322.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.68 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.27 | $5.58 |
| 52 Week High | $39.75 | $11.08 |
| Indicator | PMN | UG |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 49.31 |
| Support Level | $8.96 | $6.25 |
| Resistance Level | $17.40 | $7.41 |
| Average True Range (ATR) | 1.94 | 0.31 |
| MACD | 0.09 | -0.04 |
| Stochastic Oscillator | 50.96 | 32.58 |
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.